JPWO2020184700A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020184700A5
JPWO2020184700A5 JP2021505155A JP2021505155A JPWO2020184700A5 JP WO2020184700 A5 JPWO2020184700 A5 JP WO2020184700A5 JP 2021505155 A JP2021505155 A JP 2021505155A JP 2021505155 A JP2021505155 A JP 2021505155A JP WO2020184700 A5 JPWO2020184700 A5 JP WO2020184700A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid complex
oligonucleotide
strand
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021505155A
Other languages
English (en)
Japanese (ja)
Other versions
JP7530106B2 (ja
JPWO2020184700A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2020/011018 external-priority patent/WO2020184700A1/ja
Publication of JPWO2020184700A1 publication Critical patent/JPWO2020184700A1/ja
Publication of JPWO2020184700A5 publication Critical patent/JPWO2020184700A5/ja
Application granted granted Critical
Publication of JP7530106B2 publication Critical patent/JP7530106B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021505155A 2019-03-14 2020-03-13 Ｉｈｈ発現を調節するための核酸複合体 Active JP7530106B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019047703 2019-03-14
JP2019047703 2019-03-14
PCT/JP2020/011018 WO2020184700A1 (ja) 2019-03-14 2020-03-13 Ｉｈｈ発現を調節するための核酸複合体

Publications (3)

Publication Number Publication Date
JPWO2020184700A1 JPWO2020184700A1 (https=) 2020-09-17
JPWO2020184700A5 true JPWO2020184700A5 (https=) 2023-02-27
JP7530106B2 JP7530106B2 (ja) 2024-08-07

Family

ID=72427147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021505155A Active JP7530106B2 (ja) 2019-03-14 2020-03-13 Ｉｈｈ発現を調節するための核酸複合体

Country Status (4)

Country Link
US (1) US12492399B2 (https=)
EP (1) EP3981431A4 (https=)
JP (1) JP7530106B2 (https=)
WO (1) WO2020184700A1 (https=)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3781879B2 (ja) 1996-11-18 2006-05-31 武 今西 新規ヌクレオチド類縁体
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
EP1661905B9 (en) 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
DK1730280T3 (en) * 2004-03-26 2019-02-04 Curis Inc RNA interference modulators for hedgehog signaling and applications thereof
JP4971149B2 (ja) * 2004-06-17 2012-07-11 スラソス セラピューティックス インコーポレーテッド Ｔｄｆ関連化合物およびその類似体
EP2023940B1 (en) 2006-05-05 2011-06-22 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of sglt2
WO2008029619A1 (fr) 2006-09-07 2008-03-13 Daiichi Sankyo Company, Limited Oligonucléotide antisens ena ayant une action spécifique de la séquence
ES2603379T3 (es) 2006-10-09 2017-02-27 Roche Innovation Center Copenhagen A/S Compuestos antagonistas de ARN para la modulación de PCSK9
WO2008049085A1 (en) 2006-10-18 2008-04-24 Isis Pharmaceuticals, Inc. Antisense compounds
WO2009138516A1 (en) * 2008-05-16 2009-11-19 Galderma Research & Development Therapy regimen for treating acne related diseases
NZ601660A (en) 2008-08-25 2014-05-30 Excaliard Pharmaceuticals Inc Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
WO2011005765A1 (en) 2009-07-06 2011-01-13 Alnylam Pharmaceuticals, Inc. Bioprocessing
EP2295543A1 (en) * 2009-09-11 2011-03-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the preparation of an influenza virus
US20110183948A1 (en) 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
WO2012096545A2 (ko) * 2011-01-13 2012-07-19 연세대학교 산학협력단 췌장암 암줄기세포 특성을 이용한 췌장암 신규 바이오마커 및 그의 용도
US20120252870A1 (en) * 2011-02-19 2012-10-04 Rhode Island Hospital Indian Hedgehog (Ihh) as a Marker to Predict Osteoarthritis (OA) and Methods for the Prevention and Treatment of OA
EP2694660B1 (en) * 2011-04-03 2018-08-08 The General Hospital Corporation Efficient protein expression in vivo using modified rna (mod-rna)
KR101870915B1 (ko) * 2011-04-08 2018-06-25 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
ES2796556T3 (es) 2011-09-20 2020-11-27 Ionis Pharmaceuticals Inc Modulación antisentido de la expresión de GCGR
KR20140128257A (ko) * 2013-04-26 2014-11-05 주식회사 에이앤알티 표적 단백질 스크리닝을 위한 수용성 수용체 라이브러리 및 이를 이용한 표적 단백질 스크리닝 방법
KR20260048600A (ko) * 2015-03-27 2026-04-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 변형된 t 세포 및 이의 제조 및 사용 방법
WO2017131124A1 (ja) 2016-01-26 2017-08-03 日産化学工業株式会社 一本鎖オリゴヌクレオチド
WO2017184586A1 (en) * 2016-04-18 2017-10-26 The Trustees Of Columbia University In The City Of New York Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (nash)
CN108728440A (zh) * 2017-04-25 2018-11-02 上海吉倍生物技术有限公司 Ctla-4基因的用途及相关药物
AU2018307294B2 (en) 2017-07-26 2025-04-17 Nissan Chemical Corporation Single-stranded oligonucleotide
JP2019047703A (ja) 2017-09-07 2019-03-22 イビデン株式会社 モータ用コイル

Similar Documents

Publication Publication Date Title
Li et al. Chromatin-associated RNAs as facilitators of functional genomic interactions
US20220307019A1 (en) Double-stranded nucleic acid complex and use thereof
Lennox et al. Chemical modification and design of anti-miRNA oligonucleotides
AU2007229161B2 (en) Small internally segmented interfering RNA
TWI803455B (zh) 單股寡核苷酸
Takahashi et al. In vitro optimization of 2′-OMe-4′-thioribonucleoside–modified anti-microRNA oligonucleotides and its targeting delivery to mouse liver using a liposomal nanoparticle
JP2015502134A5 (https=)
Goodchild Therapeutic oligonucleotides
EP2400020A1 (en) Human micrornas and methods for inhibiting same
JP2014527401A5 (https=)
Elia et al. RNA (Epi) genetics in cardiovascular diseases
JP2001501614A (ja) 三つの構成成分からなるキメラアンチセンスオリゴヌクレオチド
JP2010539990A (ja) アンチセンス転写物を標的とするａｇＲＮＡおよびギャップマーを用いた遺伝子発現の調節方法
AU2019234917B2 (en) Inhibitors of micro-RNA 22
Taylor et al. Antisense oligonucleotides: a systematic high-throughput approach to target validation and gene function determination
Roux et al. Knockdown of nuclear-located enhancer RNAs and long ncRNAs using locked nucleic acid GapmeRs
Helene et al. Control of gene expression by oligodeoxynucleotides covalently linked to intercalating agents and nucleic acid-cleaving reagents
US20220154185A1 (en) HETERO DOUBLE-STRANDED antimiR
JP2014050389A (ja) マイクロ−ｒｎａおよびその前駆体にハイブリダイズしうる核酸を用いるエリスロポエチンの増加
Richards et al. RNA bandages for photoregulating in vitro protein synthesis
JP6882735B2 (ja) 構造強化されたｍｉＲＮＡ阻害剤Ｓ−ＴｕＤ
JPWO2020184700A5 (https=)
Schyth et al. In vivo screening of modified siRNAs for non-specific antiviral effect in a small fish model: number and localization in the strands are important
Yu et al. Stimulation of ribosomal frameshifting by antisense LNA
US20220135972A1 (en) Optimal ps modification pattern for heteronucleic acids